All News
Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis
Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.
Read Article
BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Read Article
RheumNow Week in Review – 30 September 2016
Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.
Read Article
NSAIDs Pose a Dose-Related Risk for Heart Failure Hospitalizations
BMJ has reported the results of a case-control study that analyzed the risk of hospitalization from heart failure associated with the use of NSAIDs amongst healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom).
Read Article
No Difference in Infection Rates Among SLE Drugs
Rates of serious infection and mortality among patients with systemic lupus erythematosus (SLE) did not depend on the immunosuppressive drug regimen they were on, investigators reported.
Read Article
FDA Approves New Amgen Biosimilar for Adalimumab
2016 has been a big year for biosimilars in rheumatology.
Read Article
After the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
Most US rheumatologists use multiple TNF inhibitors before switching. A new French study suggests that "other-MOA", non-TNF biologics are more effective after failing a TNF inhibitor.
Read Article
Demyelinating Disease is a Rare Complication of TNF Inhibition.
A recent review has shown that tumor necrosis factor-α inhibitors (TNFi) rarely cause MS-like disorders.
Read Article
New Shingles Vaccine Effective for up to Four Years
In the current issue of the NEJM, a Herpes zoster subunit vaccine was reported to be highly effective in adults - specifically in 2 studies (ZOE50 and ZOE70) targeting adults over age 50 and over age 70 years. (Citation source: http://buff.ly/2cMng17)
Read Article
DSB Reports and Updates - September 2016
Updates and journal articles on opioids, drug induced sarcoidosis, cancer and cancer recurrence risks with TNF inhibitors and biologics, and FDA labeling changes.
Read Article
Adalimumab Lowers Risk of Uveitis Flares in Visual I Study
Rheumatologists may encounter patients with intermediate, posterior and pan-uveitis as part of certain rheumatic diseases such as Behcet’s, but more frequently may be called on to co-manage these patients with steroid sparing agents.
Read Article
The RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.
Read Article
Shingles Plus Autoimmune Disease Hikes Stroke Risk
Patients with autoimmune inflammatory diseases who develop herpes zoster are at increased risk of stroke for the subsequent 3 months, with risks diminishing thereafter, analysis of Medicare data showed.
Read Article
Is Biologic Safety Different in the Elderly?
The factors that influence the safety of biologic therapy are numerous. Amongst them, increasing age is a potential risk factor, moreso if you also consider the polypharmacy, comorbidities and longer disease duration inherent in an elderly group of rheumatoid arthritis (RA) patients.
Read Article
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Another Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read Article
FDA Approves Updated Denosumab Warnings
In 2015, the Food and Drug Administration (FDA) updated the warnings of all marked bisphosphonates to include the risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read Article
Zurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.
Read Article
